News

Photo of Tyler Jacks standing in front of a wall of colorful scientific images in the Koch Institute lobby and smiling for the camera.

Tyler Jacks Receives ACS Medal of Honor

American Cancer Society

March 6, 2026

Congratulations to Koch Institute Founding Director Tyler Jacks, who has been selected to receive the 2026 American Cancer Society Medal of Honor. The organization’s highest honor, this award is given to individuals whose work has fundamentally advanced the fight against cancer. Jacks is recognized for his extraordinary scientific contributions to the field of cancer biology as well as his leadership in shaping new, more effective models for collaborative, patient-centered research at MIT, non-profit Break Through Cancer, and the national level. 

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 21–30 of 718 stories

Metabolic mixes modulate metastatic sites

Mass General Brigham

January 26, 2026

A Nature study from Matt Vander Heiden’s laboratory, in collaboration with MGB’s Rakesh Jain and Harvard’s George Church helps illuminate the factors determining where cancers can metastasize. In mice, the researchers quantified levels of metabolites in multiple tissues, investigating their relation to breast cancer cells’ ability to grow in different organs. They found a complex interplay of multiple nutrients in the local environment defines the sites of breast cancer metastases.This work was supported in part by The Bridge Project.

Remembering Richard Hynes

MIT Koch Institute

January 23, 2026

With great sadness, the Koch Institute marks the passing of Richard O. Hynes PhD ’71, whose discoveries reshaped modern understandings of how cells interact with each other and their environment, who died January 6, 2026 at age 81.

Unraveling Cancer's Safety Net

MIT Chemistry

January 14, 2026

Research from the labs of Francisco Sánchez-Rivera and Matthew Shoulders shows that tumors create an environment primed for certain dangerous mutations. The study draws on the Sanchez-Rivera group’s gene-editing tools and p53 expertise to show that elevated protein-folding networks buffer harmful TP53 variants, enabling tumor survival and growth, as well as drug resistance. 

From Nematode to Nobel

McGovern Institute

January 12, 2026

Why study worms? H. Robert Horvitz, David H. Koch (1962) Professor of Biology, with several notable former trainees and fellow Nobel laureates, makes the case in a recent PNAS paper. They highlight critical discoveries—spanning normal biology, gene regulation, and diseases including cancer—as well as research tools for imaging that have emerged from studies of a microscopic roundworm, and emphasize the community spirit and resource sharing that enabled and continue to enable this work.

Forest White Honored with Committed to Caring Award

MIT News

January 8, 2026

Congratulations to Forest White on receiving MIT’s Committed to Caring Award! This graduate student‑nominated honor recognizes faculty members whose mentorship fosters resilience, curiosity, and compassion, having a lasting impact on students’ academic and personal journeys. Forest joins 18 honorees exemplifying exceptional care and guidance in the MIT community.

Sean Luk: Addressing the urgent need for better immunotherapy  

MIT News

January 6, 2026

Motivated by her family’s cancer experiences, MIT senior Sean Luk engineers proteins in the Wittrup Lab to boost the immune system’s attack against tumors and improve cancer immunotherapies. “The complexity of the immune system really fascinated me, and it is incredible that we can build antibodies in a very logical way to address disease,” Luk says.

Predicting Peptides with CleaveNet

MIT News

January 6, 2026

Bhatia Lab researchers have developed CleaveNet, a novel AI system described in Nature Communications, to design peptides that could be cleaved efficiently and specifically by proteases of interest, such as enzymes overactive in cancer. 

How does high fat diet drive tumors?

MIT News

December 22, 2025

A new Cell study from the Shalek and Yilmaz labs suggests liver cells exposed to too much fat—via high fat diet—revert to an immature state that is more susceptible to cancer-causing mutations. Partly supported by the MIT Stem Cell Initiative, the researchers showed that chronic metabolic stress causes individual liver cells to prioritize their own survival over activities important for the tissue and organ as a whole; they also uncovered specific molecular mechanisms by which this occurs.

Sweet Sabotage: Disarming Cancer’s Sugary Defense

MIT News

December 16, 2025

Stark Lab researchers have developed a protein therapeutic that disables an immune “brake” engaged by cancer cells via cell surface sugars called glycans. A study published in Nature Biotechnology shows their multifunctional molecules, called AbLecs, can block glycan-mediated immune suppression and boost anti-cancer immune responses across multiple cancers. Combining a tumor-targeting antibody with a lectin, or glycan-binding receptor, AbLecs are now in translational development at Valora Therapeutics, co-founded by Stark.

A Shot at Simpler Antibody Treatments

MIT News

December 11, 2025

Antibody treatments for cancer and other diseases are typically delivered intravenously, requiring hours-long hospital visits for each dose. The Doyle Lab’s new approach, reported in Advanced Materials, packs highly concentrated antibodies into solid microparticles that dissolve quickly after injection, fitting full doses in a standard syringe. This makes treatment faster, easier, and more accessible for patients who have difficulty getting to a hospital.